The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich TMP, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa MSZ, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Dottino PR, Schwartz PE, Santin AD.
Han C, et al. Among authors: azodi m.
Gynecol Oncol. 2023 Mar;170:172-178. doi: 10.1016/j.ygyno.2023.01.015. Epub 2023 Jan 25.
Gynecol Oncol. 2023.
PMID: 36706643
Free PMC article.